Major clinical research advances in gynecologic cancer in 2021.

Jeong-Yeol Park; Jung-Yun Lee; Yoo-Young Lee; Seung-Hyuk Shim; Dong Hoon Suh; Jae-Weon Kim

In the 2021 series, we not only summarized the major clinical research advances in gynecologic oncology but also added discussions to every part, based on communications at the conference. A review of cervical cancer included adjuvant treatments such as radiation and chemoradiation (concurrent or sequential) after radical hysterectomy in early cervical cancer, and immune checkpoint inhibitors in advanced, recurrent, and metastatic disease. Ovarian cancer research included studies of secondary cytoreductive surgery in platinumsensitive recurrent ovarian cancer, and various trials of immune checkpoint inhibitors with or without vascular endothelial growth factor inhibitors and conventional chemotherapy. The rechallenge of poly (ADP-ribose) polymerase inhibitor maintenance in heavily pretreated ovarian cancer were also addressed. For uterine corpus cancer, dostarlimab (anti-programmed cell death protein 1 antibody) alone, or a tyrosine kinase inhibitor in combination with pembrolizumab for advanced, metastatic, or recurrent endometrial cancer were reviewed. The survival differences between the intensive and minimalist follow-up protocols were also described. In this review, we compared salpingectomy with delayed oophorectomy and salpingo-oophorectomy in terms of quality of life in BRCA 1 and 2 pathogenic variant carriers.

CHEMORADIOTHERAPY; MEDICAL research; GYNECOLOGIC cancer; VASCULAR endothelial growth factor antagonists; ADJUVANT treatment of cancer; GYNECOLOGIC oncology

Journal of Gynecologic Oncology, 2022, Vol 33, Issue 2, p1

2005-0380

Academic Journal

10.3802/jgo.2022.33.e43